GlassScriptPhysician profile
Madison Kendrick
NPI 1033700885
$2,574.61
in general payments reported to CMS, 2019-2025
21 companies · $1,031 in 2025
The $1,031 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $53.49 · 2024: $1,491 · 2025: $1,031.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,359 · Education: $162.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,359.14 |
| Education | $161.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $810.26 | 2024-2025 | Fasenra, Breztri, Tezspire |
| Actelion Pharmaceuticals US, INC. | $412.01 | 2024-2025 | Opsumit, Uptravi |
| Genzyme Corporation | $234.00 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $186.37 | 2025 | Dupixent |
| Mallinckrodt Hospital Products INC. | $158.09 | 2024-2025 | Acthar |
| Glaxosmithkline, LLC. | $151.90 | 2024-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $113.63 | 2024-2025 | Glassia, Cuvitru |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.09 | 2024-2025 | Ofev, Stiolto Respimat |
| Abbvie INC. | $63.14 | 2025 | |
| Baxter Healthcare | $61.50 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Mylan Specialty L.P. | $51.52 | 2024 | Yupelri |
| Verona Pharma, INC. | $41.16 | 2025 | Ohtuvayre |
| Grifols USA, LLC | $39.38 | 2024-2025 | Prolastin-C Liquid |
| Pfizer INC. | $38.78 | 2024-2025 | |
| Amgen INC. | $28.88 | 2024 | Tezspire |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $24.88 | 2021 | |
| United Therapeutics Corporation | $23.13 | 2024 | Tyvaso |
| Philips North America LLC | $19.70 | 2024 | (Ak6) Vest Therapy |
| Merck Sharp & Dohme LLC | $18.58 | 2024 | Zerbaxa |
| Neurelis, INC. | $16.07 | 2021 | |
| Livanova USA, INC. | $12.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madison Kendrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.